Cipla has signed a non-exclusive licensing agreement with MSD a tradename of Merck & Co., Inc. Kenilworth, NJ., USA for the manufacturing and distribution of Molnupiravir, the investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19. MSD is developing Molnupiravir in collaboration with Ridgeback Biotherapeutics. This agreement is a part of Cipla’s efforts to enhance global access to treatments for patients affected by the pandemic.
As part of the agreement, Cipla will be permitted to manufacture, market and distribute Molnupiravir in India and more than 100 low and middle income countries. Cipla’s extensive geographical and commercial footprint will help make this therapy accessible to more patients and markets.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
